Document Detail


Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
MedLine Citation:
PMID:  2234245     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity. 6 patients presented clinical symptoms of visual or auditory toxicity. Moreover, detailed ophthalmologic and audiologic studies disclosed abnormalities in 7 more asymptomatic patients. Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits. Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type. Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3. This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels. The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine. Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible.
Authors:
A Cases; J Kelly; F Sabater; A Torras; M C Griño; J Lopez-Pedret; L Revert
Related Documents :
17629815 - Asymptomatic visual field disturbances in multiple sclerosis patients without a history...
6678375 - Contrast sensitivity of hemodialysis patients.
2345615 - Optic neuritis: a prospective study.
15799745 - Valsalva retinopathy: diagnostic challenges in a patient with pars-planitis.
21864725 - Predictors of nocturnal oxyhemoglobin desaturation in copd.
6701265 - Alexithymia in chronic bronchitis/emphysema patients. communication of subjective sympt...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nephron     Volume:  56     ISSN:  0028-2766     ISO Abbreviation:  Nephron     Publication Date:  1990  
Date Detail:
Created Date:  1990-12-10     Completed Date:  1990-12-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0331777     Medline TA:  Nephron     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  19-23     Citation Subset:  IM    
Affiliation:
Nephrology Service, Hospital Clinic i Provincial, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Aluminum
Chelation Therapy
Deferoxamine / adverse effects*,  therapeutic use
Female
Hearing Loss, Bilateral / chemically induced*
Hearing Loss, Sensorineural / chemically induced*
Humans
Iron
Male
Middle Aged
Prospective Studies
Renal Dialysis / adverse effects
Retinal Diseases / chemically induced
Vision Disorders / chemically induced*
Chemical
Reg. No./Substance:
70-51-9/Deferoxamine; 7429-90-5/Aluminum; 7439-89-6/Iron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro production of 'glomerular red cells': role of pH and osmolality.
Next Document:  Urinary excretion of apolipoproteins bound to HDL-like particles in rat nephrotic syndrome and their...